- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01245062
GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
A Phase III Randomized, Open-label Study Comparing GSK1120212 to Chemotherapy in Subjects With Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Berlin, Alemania, 10117
- GSK Investigational Site
-
-
Baden-Wuerttemberg
-
Heidelberg, Baden-Wuerttemberg, Alemania, 69120
- GSK Investigational Site
-
Mannheim, Baden-Wuerttemberg, Alemania, 68167
- GSK Investigational Site
-
Tuebingen, Baden-Wuerttemberg, Alemania, 72076
- GSK Investigational Site
-
-
Bayern
-
Muenchen, Bayern, Alemania, 80804
- GSK Investigational Site
-
Wuerzburg, Bayern, Alemania, 97080
- GSK Investigational Site
-
-
Niedersachsen
-
Buxtehude, Niedersachsen, Alemania, 21614
- GSK Investigational Site
-
-
Nordrhein-Westfalen
-
Essen, Nordrhein-Westfalen, Alemania, 45122
- GSK Investigational Site
-
-
Sachsen
-
Dresden, Sachsen, Alemania, 01307
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Luebeck, Schleswig-Holstein, Alemania, 23538
- GSK Investigational Site
-
-
-
-
-
Ciudad Autonoma de Buenos Aires, Argentina, C1121ABE
- GSK Investigational Site
-
-
-
-
Australian Capital Territory
-
Garran, Australian Capital Territory, Australia, 2606
- GSK Investigational Site
-
-
New South Wales
-
Port Macquarie, New South Wales, Australia, 2444
- GSK Investigational Site
-
Waratah, New South Wales, Australia, 2300
- GSK Investigational Site
-
-
Queensland
-
South Brisbane, Queensland, Australia, 4101
- GSK Investigational Site
-
Townsville, Queensland, Australia, 4810
- GSK Investigational Site
-
Woolloongabba, Queensland, Australia, 4102
- GSK Investigational Site
-
-
South Australia
-
Kurralta Park, South Australia, Australia, 5037
- GSK Investigational Site
-
Woodville, South Australia, Australia, 5011
- GSK Investigational Site
-
-
Victoria
-
Heidelberg, Victoria, Australia, 3084
- GSK Investigational Site
-
Melbourne, Victoria, Australia, 3004
- GSK Investigational Site
-
-
-
-
-
Graz, Austria, 8036
- GSK Investigational Site
-
Wien, Austria, 1090
- GSK Investigational Site
-
-
-
-
-
Brussels, Bélgica, 1200
- GSK Investigational Site
-
Charleroi, Bélgica, 6000
- GSK Investigational Site
-
Gent, Bélgica, 9000
- GSK Investigational Site
-
Jette, Bélgica, 1090
- GSK Investigational Site
-
Kortrijk, Bélgica, 8500
- GSK Investigational Site
-
Leuven, Bélgica, 3000
- GSK Investigational Site
-
Wilrijk, Bélgica, 2610
- GSK Investigational Site
-
Yvoir, Bélgica, 5530
- GSK Investigational Site
-
-
-
-
Alberta
-
Calgary, Alberta, Canadá, T2N 4N2
- GSK Investigational Site
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V5Z 4E6
- GSK Investigational Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canadá, B3H 2Y9
- GSK Investigational Site
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8V 5C2
- GSK Investigational Site
-
London, Ontario, Canadá, N6A 4L6
- GSK Investigational Site
-
Oshawa, Ontario, Canadá, L1G 2B9
- GSK Investigational Site
-
Ottawa, Ontario, Canadá, K1H 8L6
- GSK Investigational Site
-
Toronto, Ontario, Canadá, M5G 2M9
- GSK Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canadá, H2L 4M1
- GSK Investigational Site
-
Montreal, Quebec, Canadá, H2W 1S6
- GSK Investigational Site
-
-
-
-
-
Hradec Kralove, Chequia, 500 05
- GSK Investigational Site
-
Ostrava, Chequia, 708 52
- GSK Investigational Site
-
Praha 2, Chequia, 128 08
- GSK Investigational Site
-
Zlin, Chequia, 76275
- GSK Investigational Site
-
-
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 85724-5024
- GSK Investigational Site
-
-
Florida
-
Fort Myers, Florida, Estados Unidos, 33916
- GSK Investigational Site
-
-
Georgia
-
Athens, Georgia, Estados Unidos, 30607
- GSK Investigational Site
-
Marietta, Georgia, Estados Unidos, 30060
- GSK Investigational Site
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- GSK Investigational Site
-
-
Louisiana
-
Metairie, Louisiana, Estados Unidos, 70006
- GSK Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- GSK Investigational Site
-
-
New Jersey
-
Morristown, New Jersey, Estados Unidos, 07962-1956
- GSK Investigational Site
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43210
- GSK Investigational Site
-
-
South Carolina
-
Columbia, South Carolina, Estados Unidos, 29210
- GSK Investigational Site
-
-
Tennessee
-
Chattanooga, Tennessee, Estados Unidos, 37404
- GSK Investigational Site
-
Memphis, Tennessee, Estados Unidos, 38120
- GSK Investigational Site
-
Nashville, Tennessee, Estados Unidos, 37203
- GSK Investigational Site
-
-
-
-
-
Chelyabinsk, Federación Rusa, 454087
- GSK Investigational Site
-
Magnitogorsk, Federación Rusa, 455001
- GSK Investigational Site
-
Moscow, Federación Rusa, 115478
- GSK Investigational Site
-
St. Petersburg, Federación Rusa, 197758
- GSK Investigational Site
-
-
-
-
-
Boulogne-Billancourt, Francia, 92100
- GSK Investigational Site
-
Grenoble, Francia, 38043
- GSK Investigational Site
-
Montpellier, Francia, 34295
- GSK Investigational Site
-
Nantes, Francia, 44093
- GSK Investigational Site
-
Paris Cedex 10, Francia, 75475
- GSK Investigational Site
-
Pierre-Benite cedex, Francia, 69495
- GSK Investigational Site
-
Rennes, Francia, 35042
- GSK Investigational Site
-
Tours, Francia, 37044
- GSK Investigational Site
-
Villejuif, Francia, 94805
- GSK Investigational Site
-
-
-
-
-
Athens, Grecia, 11527
- GSK Investigational Site
-
Athens, Grecia, 185 47
- GSK Investigational Site
-
Thessaloniki, Grecia, 564 29
- GSK Investigational Site
-
-
-
-
Lombardia
-
Milano, Lombardia, Italia, 20132
- GSK Investigational Site
-
Milano, Lombardia, Italia, 20133
- GSK Investigational Site
-
Milano, Lombardia, Italia, 20141
- GSK Investigational Site
-
-
Toscana
-
Pisa, Toscana, Italia, 56126
- GSK Investigational Site
-
-
-
-
-
Oslo, Noruega, 0310
- GSK Investigational Site
-
-
-
-
-
Christchurch, Nueva Zelanda, 8011
- GSK Investigational Site
-
Dunedin, Nueva Zelanda, 9016
- GSK Investigational Site
-
Newtown, Wellington, Nueva Zelanda, 6002
- GSK Investigational Site
-
-
-
-
-
Poznan, Polonia, 61-866
- GSK Investigational Site
-
Warszawa, Polonia, 02-781
- GSK Investigational Site
-
Warszawa, Polonia, 04-125
- GSK Investigational Site
-
-
-
-
-
Aberdeen, Reino Unido, AB25 2ZN
- GSK Investigational Site
-
Birmingham, Reino Unido, B15 2TH
- GSK Investigational Site
-
Chelmsford, Reino Unido, CM1 7ET
- GSK Investigational Site
-
Leeds, Reino Unido, LS9 7TF
- GSK Investigational Site
-
London, Reino Unido, SW3 6JJ
- GSK Investigational Site
-
London, Reino Unido, W1G 6AD
- GSK Investigational Site
-
Manchester, Reino Unido, M20 4BX
- GSK Investigational Site
-
Oxford, Reino Unido, OX3 7LJ
- GSK Investigational Site
-
Southampton, Reino Unido, SO16 6YD
- GSK Investigational Site
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Reino Unido, CB2 2QQ
- GSK Investigational Site
-
-
Middlesex
-
Northwood, Middlesex, Reino Unido, HA6 2RN
- GSK Investigational Site
-
-
Surrey
-
Sutton, Surrey, Reino Unido, SM2 5PT
- GSK Investigational Site
-
-
-
-
-
Goteborg, Suecia, SE-413 45
- GSK Investigational Site
-
Linkoping, Suecia, SE-581 85
- GSK Investigational Site
-
Lund, Suecia, SE-221 85
- GSK Investigational Site
-
Stockholm, Suecia, SE-171 76
- GSK Investigational Site
-
Uppsala, Suecia, SE-751 85
- GSK Investigational Site
-
-
-
-
-
Zurich, Suiza, 8091
- GSK Investigational Site
-
-
-
-
-
Dnepropetrovsk, Ucrania, 49102
- GSK Investigational Site
-
Kharkiv, Ucrania, 61070
- GSK Investigational Site
-
Kyiv, Ucrania, 03022
- GSK Investigational Site
-
Kyiv, Ucrania, 03115
- GSK Investigational Site
-
Lviv, Ucrania, 79031
- GSK Investigational Site
-
Sumy, Ucrania, 40005
- GSK Investigational Site
-
Sympheropol, Ucrania, 95023
- GSK Investigational Site
-
Ternopil, Ucrania, 46023
- GSK Investigational Site
-
Uzhgorod, Ucrania, 88017
- GSK Investigational Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- ≥18 years of age
- Stage III unresectable (Stage IIIc) or metastatic (Stage IV) cutaneous melanoma which is also determined to be BRAF V600E/K mutation-positive by the central laboratory
- Received no prior treatment or up to one prior regimen of chemotherapy for advanced or metastatic melanoma. Prior treatment with immunotherapy (with the exception of prior ipilimumab, which is only allowed if given in the adjuvant setting), cytokine therapy, biological or vaccine regimen is permitted. Prior use of sorafenib is allowed
- Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
- Women of childbearing potential and men with reproductive potential must agree to use effective contraception during the study. Additionally women of childbearing potential must have a negative serum pregnancy test within 14 days prior to randomization
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
- Adequate screening organ function
Exclusion Criteria:
- Any prior use of BRAF inhibitors or MEK inhibitors.
- Subjects who have received dacarbazine or paclitaxel prior to randomization will not be eligible to receive the same chemotherapy as study medication (i.e. a subject who received prior dacarbazine cannot receive dacarbazine on this trial and would thus receive paclitaxel if randomized to the control arm)
- History of another malignancy. Exception: Subjects who have been disease-free for 3 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible. Subjects with second malignancies that are indolent or definitively treated may be enrolled. Consult GSK Medical Monitor if unsure whether second malignancies meet requirements specified above
- Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection which will be allowed)
- Brain metastases with the following exceptions that are ALL confirmed by the GSK Medical Monitor:
All known lesions must be previously treated with surgery or stereotactic radiosurgery, and Brain lesion(s), if still present, must be confirmed stable (i.e. no increase in lesion size) for ≥90 days prior to randomization (must be documented with two consecutive MRI or CT scans using contrast), and asymptomatic with no corticosteroids requirement for ≥ 30 days prior to randomization, and no enzyme-inducing anticonvulsants for ≥ 30 days prior to randomization
History or evidence of cardiovascular risk including any of the following:
- QTcB ≥ 480 msec.
- History or evidence of current clinically significant uncontrolled arrhythmias. Exception: Subjects with controlled atrial fibrillation for >30 days prior to randomization are eligible
- History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization.
- History or evidence of current ≥ Class II congestive heart failure as defined by New York Heart Association
- History of interstitial lung disease or pneumonitis
History or current evidence / risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR):
- History of RVO or CSR, or predisposing factors to RVO or CSR (e.g. uncontrolled glaucoma or ocular hypertension, uncontrolled hypertension, uncontrolled diabetes mellitus, or history of hyperviscosity or hypercoagulability syndromes).
- Visible retinal pathology as assessed by ophthalmic exam that is considered a risk factor for RVO or CSR such as:
- Evidence of new optic disc cupping.
- Intraocular pressure > 21 mm Hg as measured by tonography
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: GSK1120212
MEK inhibitor
|
Inhibidor de MEK
|
Comparador activo: Chemotherapy
Investigator Choice of DTIC or paclitaxel
|
Investigator Choice of DTIC or paclitaxel
|
Experimental: Crossover
MEK inhibitor after documented progression on Chemotherapy Arm
|
Inhibidor de MEK
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Progression-free Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases as Assessed by the Investigator and Independent Review
Periodo de tiempo: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
Progression-free survival (PFS) is defined as the time from randomization to the first documented occurrence of disease progression (PD) or death.
PFS for investigator-assessed and blinded, independent, central review committee (BRIC)-assessed responses was summarized per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1, which is a set of published rules defining when cancer participants improve (respond), stay the same (stabilize), or worsen (progress) during treatment.
Disease progression is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 millimeters (mm) or the appearance of at least 1 new lesion, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
Primary Efficacy Population included all participants with BRAF V600E mutation-positive melanoma without a history of brain metastases.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Progression-free Survival in All Participants
Periodo de tiempo: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
PFS is defined as the time from the date of randomization to the first documented occurrence of PD or death.
Investigator-assessed and BRIC-assessed PFS were summarized per RECIST, Version 1.1.
PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
Intend-To-Treat (ITT) Population included all randomized participants regardless of whether or not treatment was administered.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
PFS in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases and Without Prior Chemotherapy as Assessed by the Investigator
Periodo de tiempo: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
PFS is defined as the time from the date of randomization to the first documented occurrence of PD or death.
Investigator-assessed PFS was summarized per RECIST, Version 1.1.
PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
PFS in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases and With Prior Chemotherapy as Assessed by the Investigator
Periodo de tiempo: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
PFS is defined as the time from the date of randomization to the first documented occurrence of PD or death.
Investigator-assessed PFS was summarized per RECIST, Version 1.1.
PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
Overall Survival in All Participants
Periodo de tiempo: Day 1 until death due to any cause (average of 20.3 months)
|
Overall survival was defined as the time from the date of randomization to the date of death due to any cause.
|
Day 1 until death due to any cause (average of 20.3 months)
|
Overall Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases
Periodo de tiempo: Day 1 until death due to any cause (average of 20.3 months)
|
Overall survival was defined as the time from the date of randomization to the date of death due to any cause.
NA indicates data was not available.
|
Day 1 until death due to any cause (average of 20.3 months)
|
Number of BRAF V600E Mutation-positive Participants Without a History of Brain Metastases With Overall Response (OR) as Assessed by the Investigator and Independent Review
Periodo de tiempo: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
OR is defined as the number of participants with evidence of complete response (CR; disappearance of all target lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator and an independent review per RECIST, Version 1.1.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
Number of Participants With OR as Assessed by the Investigator and Independent Review
Periodo de tiempo: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
OR is defined as the number of participants with evidence of complete response (disappearance of all target lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or partial response (at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator and an independent review per RECIST, Version 1.1.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
Number of BRAF V600E Mutation-positive Participants Classified as Confirmed Responders (CR and PR) as Assessed by the Investigator
Periodo de tiempo: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
OR is defined as the number of participants with evidence of complete response (disappearance of all extranodal lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or partial response (at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator per RECIST, Version 1.1.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
Number of BRAF V600K Mutation-positive Participants Classified as Confirmed Responders (CR and PR) as Assessed by the Investigator
Periodo de tiempo: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
OR is defined as the number of participants with evidence of complete response (CR; disappearance of all extranodal lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator per RECIST, Version 1.1.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
Number of Participants With OR Following Cross-over to Trametinib
Periodo de tiempo: Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
|
OR is defined as the number of participants with evidence of CR (disappearance of all target lesions.
Any pathological lymph node must be less than 10 millimeters in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator in participants following cross-over to Trametinib.
The evaluation was carried out by the Investigator per RECIST, Version 1.1.
Cross-over Population included the subset of participants who were randomized to CT and who elected to cross-over to Trametinib following disease progression on CT.
Only participants who received at least one dose of Trametinib were included in this population.
|
Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
|
Duration of Response (DoR) for All BRAF V600E Mutation-positive Participants Without a Prior History of Brain Metastases Classified as Confirmed Responders (CR or PR) as Assessed by the Investigator Review
Periodo de tiempo: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
DoR is defined as the time from the first documented evidence of CR (disappearance of all target lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD (at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation) or death due to any cause.
DoR for the investigator-assessed (INVA) response data were summarized per RECIST, Version 1.1.
Only those participants with confirmed response (CR and PR) were analyzed.
Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
NA indicates data was not available.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
DoR for All BRAF V600E Mutation-positive Participants Without a Prior History of Brain Metastases Classified as Confirmed Responders (CR or PR) as Assessed by the Independent Review
Periodo de tiempo: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
DoR is defined as the time from the first documented evidence of CR (disappearance of all target lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD (at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation) or death due to any cause.
DoR for the independently-assessed (INDA) response data were summarized per RECIST, Version 1.1.
Only those participants with confirmed response (CR and PR) were analyzed.
Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
NA indicates data was not available.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
DoR for All Confirmed Responders (CR or PR) as Assessed by the Investigator Review
Periodo de tiempo: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
DoR is defined as the time from the first documented evidence of CR (disappearance of all target lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD or death due to any cause.
PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
DoR for the INVA response data was summarized per RECIST, Version 1.1.
Only those participants with confirmed response (CR and PR) were analyzed.
Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
NA indicates data was not available.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
DoR for All Confirmed Responders (CR or PR) as Assessed by the Independent Review
Periodo de tiempo: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
DoR is defined as the time from the first documented evidence of CR (disappearance of all target lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD or death due to any cause.
PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
DoR for the INDA response data was summarized per RECIST, Version 1.1.
Only those participants with confirmed response (CR and PR) were analyzed.
Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
NA indicates data was not available.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
DoR for All Responders (CR or PR) Following Cross-over to Trametinib as Assessed by the Investigator
Periodo de tiempo: Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
|
DoR is defined as the time from the first documented evidence of CR (disappearance of all extra nodal lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD or death due to any cause.
PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
DoR data were summarized per RECIST, Version 1.1Only those participants with confirmed response (CR and PR) were analyzed.
Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
NA indicates data was not available.
|
Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
|
PFS Following Cross-over to Trametinib as Assessed by the Investigator
Periodo de tiempo: Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
|
PFS is defined as the time from the first dose of cross-over therapy to the first documented occurrence of PD or death.
PFS was summarized per RECIST, Version 1.1.
PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
|
Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- Santiago-Walker A, Gagnon R, Mazumdar J, Casey M, Long GV, Schadendorf D, Flaherty K, Kefford R, Hauschild A, Hwu P, Haney P, O'Hagan A, Carver J, Goodman V, Legos J, Martin AM. Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. Clin Cancer Res. 2016 Feb 1;22(3):567-74. doi: 10.1158/1078-0432.CCR-15-0321. Epub 2015 Oct 7.
- Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012 Jul 12;367(2):107-14. doi: 10.1056/NEJMoa1203421. Epub 2012 Jun 4.
- Robert C, Flaherty K, Nathan P, Hersey P, Garbe C, Milhem M, Demidov L, Mohr P, Hassel JC, Rutkowski P, Dummer R, Utikal J, Kiecker F, Larkin J, D'Amelio A Jr, Mookerjee B, Schadendorf D. Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma. Eur J Cancer. 2019 Mar;109:61-69. doi: 10.1016/j.ejca.2018.12.015. Epub 2019 Jan 25.
- Latimer NR, Bell H, Abrams KR, Amonkar MM, Casey M. Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy. Cancer Med. 2016 May;5(5):806-15. doi: 10.1002/cam4.643. Epub 2016 Jan 27.
- Schadendorf D, Amonkar MM, Milhem M, Grotzinger K, Demidov LV, Rutkowski P, Garbe C, Dummer R, Hassel JC, Wolter P, Mohr P, Trefzer U, Lefeuvre-Plesse C, Rutten A, Steven N, Ullenhag G, Sherman L, Wu FS, Patel K, Casey M, Robert C. Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. Ann Oncol. 2014 Mar;25(3):700-706. doi: 10.1093/annonc/mdt580. Epub 2014 Feb 6.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias por tipo histológico
- Neoplasias
- Tumores neuroectodérmicos
- Neoplasias De Células Germinales Y Embrionarias
- Neoplasias De Tejido Nervioso
- Tumores neuroendocrinos
- Nevos y Melanomas
- Melanoma
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Agentes antineoplásicos
- Inhibidores de la proteína quinasa
- Trametinib
Otros números de identificación del estudio
- 114267
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre GSK1120212
-
Novartis PharmaceuticalsTerminadoCáncerFrancia, Estados Unidos, Países Bajos, Canadá, Taiwán, Corea, república de
-
National Cancer Institute (NCI)Activo, no reclutandoNeoplasia sólida maligna avanzada | Neoplasia sólida maligna metastásica | Neoplasia maligna metastásica en el hígado | Neoplasia sólida irresecableEstados Unidos, Canadá
-
National Cancer Institute (NCI)Children's Oncology GroupActivo, no reclutandoLeucemia mielomonocítica juvenil | Neurofibromatosis tipo 1Estados Unidos
-
Jonsson Comprehensive Cancer CenterNovartis; Stand Up To Cancer; Prostate Cancer FoundationActivo, no reclutandoCarcinoma de próstata metastásico | Carcinoma de próstata recurrente | Cáncer de próstata en estadio IV | Cáncer de próstata resistente a hormonasEstados Unidos
-
National Cancer Institute (NCI)TerminadoHemangioendotelioma epitelioide localmente avanzado | Hemangioendotelioma epitelioide metastásico | Hemangioendotelioma epitelioide irresecableEstados Unidos
-
National Cancer Institute (NCI)TerminadoMieloma de células plasmáticas refractario | Mieloma de células plasmáticas recurrenteCanadá
-
City of Hope Medical CenterNational Cancer Institute (NCI)ReclutamientoCarcinoma anaplásico de la glándula tiroides | Mutación BRAF V600K presente | BRAF NP_004324.2:p.V600EEstados Unidos
-
National Cancer Institute (NCI)TerminadoMelanoma uveal en estadio IV AJCC v7 | Melanoma uveal recurrenteEstados Unidos, Francia, Reino Unido
-
National Cancer Institute (NCI)GlaxoSmithKlineTerminadoCáncer de mama en estadio IV | Carcinoma de mama recurrente | Carcinoma de mama invasivo | Receptor de estrógeno negativo | HER2/Neu Negativo | Receptor de progesterona negativo | Carcinoma de mama triple negativoEstados Unidos
-
University of UtahNovartis PharmaceuticalsReclutamientoCarcinoma de páncreas metastásico | Carcinoma de páncreas irresecable | Cáncer de páncreas en estadio III | Cáncer de páncreas en estadio IV | Cáncer de páncreas en estadio IIA | Cáncer de páncreas en estadio IIB | Cáncer de páncreas en estadio IIEstados Unidos